

## *Oregon's Opioid Settlements*

The United States is in the **midst of a crisis** on its streets and in its communities as **overdoses, homelessness, and disorder reach record levels**. Yet settlement proceeds secured by the State of Oregon present an **unprecedented opportunity for generational investment** in treatment capacity for chronic substance abuse (CSA) and severe mental illness (SMI).

Oregon is set to receive **nearly \$725 million** (\$722,877,045.09) in opioid settlement funds—equal to one-third of the state's share of the monumental Tobacco Master Settlement Agreement.<sup>1</sup> With twenty-one separate settlements and payments spread out over decades, the funds are **at risk of being squandered** through ad-hoc allocations to **diffuse and disorganized efforts**.

The state must ensure that this opportunity for treatment investment is not underutilized. **Oregon can make targeted investments in treatment capacity** that will **honor those who suffered** in the opioid crisis and **ensure accessible care** for decades to come.

Oregon reserves 45 percent (\$330,459,279.61) of funds for use by the state and allocates the remainder to subdivisions.<sup>2</sup> <sup>1</sup> The 18-person Opioid Settlement Prevention and Recovery Board is in charge of making final allocations from the Opioid Settlement Prevention, Treatment, and Recovery Fund, though the Oregon Health Authority is technically the recipient of the funds.<sup>3</sup> The Board allocated \$46 million (excluding Tribal allocations) as of the latest report, with most funds allocated toward primary prevention and recovery priorities.<sup>4</sup> It's unclear whether the "Recovery Community Centers" which received the bulk of funds are a better use of funds than the priorities below. **The state should amend statute to vest ultimate allocation authority in the legislature.**

The state must rein in the potential misallocation of these funds and prioritize investments in comprehensive treatment networks. **Three priorities** (Certified Community Behavioral Health Clinics, secure psychiatric beds, and community SMI/CSA response) **will ensure these funds have the largest impact** on Oregon.

---

<sup>1</sup>With the exception of the McKinsey and Publicis settlements, in which the state controls 100 percent of funds.

## Certified Community Behavioral Health Clinics (CCBHCs)

CCBHCs, designed to ensure access to coordinated comprehensive behavioral health care, have stable funding and are supported by all recent presidential administrations. CCBHCs are a key response to the opioid crisis and can augment other services such as police crisis response teams, homelessness outreach and services, and outpatient psychiatric commitment services.

- **Solution: Fund the development and expansion of CCBHCs.**
  - o Expand the CCBHC footprint with an emphasis on a team-based approach to co-occurring disorders.
  - o Create a stepped approach to SMI/CSA treatment with services provided by the CCBHCs.
  - o Require CCBHCs to offer specific care pathways to meet the needs of individuals with co-occurring disorders.

## State Psychiatric Hospitals

Inpatient beds in secure facilities are critical for serving the highest-acuity psychiatric patients. Oregon currently has only **1.2 state psychiatric beds** per 100,000 people available for civil (i.e., non-criminal) patients.<sup>5,6</sup> Treatment Advocacy Center recommends a rate of 30-60 beds per 100,000. Even counting non-public secure psychiatric beds, Oregon still falls short of the minimum.<sup>7</sup> Secure beds are a costly but necessary expenditure to protect patients with severe psychiatric disorders and the public at large.

- **Solution: Fund the expansion of civil psychiatric beds.**
  - o Invest in expanding state hospital capacity.
  - o Move forensic (criminal) commitments to a jail-based restoration facility.
  - o Apply for one of several Section 1115(a) waivers to expand Medicaid reimbursement for institutions for mental diseases (IMDs).

## Inpatient Stabilization Centers and Mobile Crisis Teams

Emergency departments (EDs) are supposed to be a last resort for times of true emergencies but are increasingly used for all types of immediate-need medical care. This is especially true for low- to medium-acuity mental health crises. In order for CCBHCs and state psychiatric bed expansions to have the largest impact, there must be an immediate triage of low-acuity patients from higher-need patients, or else investments in these facilities will be drowned out, overburdened, and underutilized by those that need them most, just like emergency departments.

- **Solution: Fund community-based mental health response resources.**
  - Expand community-based recovery centers, including voluntary short-term respite housing, especially for young adults.
  - Leverage CCBHC resources to develop comprehensive mobile crisis response teams in conjunction with police crisis intervention teams (CIT).
  - Support integration of community resources with crisis networks such as the Lifeline to support those in need or provide guidance for concerned loved ones.

## OREGON

[Download all Oregon opioid settlement documents](#)

[View settlement fund dashboard](#)

STATE-CONTROLLED FUNDS	ALL FUNDS	2025 EOY FUNDS RECEIVED - STATE	2025 EOY FUNDS RECEIVED - ALL	Av. Receipt (All Funds) / Yr (*20)
\$330,459,279.61	\$722,877,045.09	\$114,938,728.38	\$244,512,865.97	\$36,143,852.25

### 2021 National Opioid Settlement

*Oregon v. Distributors*

- [Stipulated General Judgment](#)
  - Exhibit 1 “Distributor Settlement Agreement” [p. 14]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 584]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. McKesson Corporation, et al., Multnomah County Circuit Court, Case No. 22CV10816

*Oregon v. Janssen*

- [Stipulated General Judgment](#)
  - Exhibit 1 “Janssen Settlement Agreement” [p. 15]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 523]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Johnson & Johnson, et al., Multnomah County Circuit Court, Case No. 22CV12497

### 2022 National Opioid Settlement

*Oregon v. CVS*

- [Final Stipulated General Judgment](#)
  - Exhibit 1 “agreement dated as of December 9 2022” [p. 15]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 726]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. CVS Pharmacy, Inc., Multnomah County Circuit Court, Case No. 23cv46419

*Oregon v. Walgreens*

- [Final Stipulated General Judgment](#)
  - Exhibit 1 “agreement dated as of December 9, 2022” [p. 13]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 837]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Walgreen Co., Multnomah County Circuit Court, Case No. 23CV44231

*Oregon v. Walmart*

- [Final Stipulated Judgment](#)
  - Exhibit 1 “agreement dated as of November 14, 2022” [p. 14]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 596]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Walmart Inc., Multnomah County Circuit Court, Case No. 23CV44606

*Oregon v. Allergan*

- [Final Stipulated Limited Judgment](#)
  - Exhibit 1 “Allergan Public Global Opioid Settlement Agreement” [p. 12]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 568]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Allergan Finance, LLC (F/K/A Actavis, Inc., F/K/A Watson Pharmaceuticals, Inc.) and Allergan Limited (F/K/A Allergan PLC, F/K/A Actavis PLC), Multnomah County Circuit Court, Case No. 23CV36190

*Oregon v. Teva*

- [Stipulated General Judgment](#)
  - Exhibit 1 “Teva Global Opioid Settlement Agreement” [p. 12]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 579]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Teva Pharmaceutical Industries, Ltd., et al., Multnomah County Circuit Court, Case No. 23CV36190

**Other Coalition Opioid Settlements***Oregon v. Kroger*

- [Final Stipulated Judgment](#)
  - Exhibit 1 “agreement dated as of March 22 2024” [p. 12]
  - Exhibit 2 “State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds” [p. 523]
  - Exhibit 2.1 “Oregon Supplement to Statewide Allocation Agreement” [p. 535]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. The Kroger Co., Multnomah County Circuit Court, Case No. 24CV59987

*Oregon v. McKinsey*

- [Stipulated General Judgment](#)
- [McKinsey Allocation Amounts](#)
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. McKinsey & Company, Inc. United States, Multnomah County Circuit Court, Case No. [ ]

*Oregon v. Mallinckrodt*

- [NOAT II Agreement](#)
- [Statewide Abatement Agreement](#)
- [Notice of Abatement Distribution](#)

*Oregon v. Publicis*

- [Stipulated General Judgment](#)
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon, v. Publicis Health, LLC, Multnomah County Circuit Court, Case No. 24CV05149

*Oregon v. Endo*

- [Global Public Trust Agreement](#)
- [Notice of Abatement Distribution](#)

**2025 National Settlements**

*Oregon v. Purdue*

- [missing documentation]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon v. Purdue Pharma L.P., et al., Circuit Court of Multnomah County, Case No. 18CV40526 [unconfirmed]
- State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon v. Richard S. Sackler., et al., Circuit Court of Multnomah County, Case No. 19CV22185 [unconfirmed]

*Oregon v. Mylan*

- [missing documentation]

*Oregon v. Amneal*

- [missing documentation]

*Oregon v. Apotex*

- [missing documentation]

*Oregon v. Indivior*

- [missing documentation]

*Oregon v. Sun Pharmaceuticals*

- [missing documentation]

*Oregon v. Alvogen*

- [missing documentation]

*Oregon v. Zydus*

- [missing documentation]

**Independent Settlements**

---

<sup>1</sup> KFF. "Actual Tobacco Settlement Payments Received by the States (in millions)." Accessed 8 September 2025.

<https://www.kff.org/health-costs/state-indicator/tobacco-settlement-payments>.

<sup>2</sup> "State of Oregon Subdivision Agreement Regarding Distribution and Use of Settlement Funds."

[https://drive.google.com/file/d/1naJHbOlal3\\_Qex-ALQbbiTP8ugSNRaVH/view?usp=sharing](https://drive.google.com/file/d/1naJHbOlal3_Qex-ALQbbiTP8ugSNRaVH/view?usp=sharing).

<sup>3</sup> Sections 4-8, Chapter 63, Oregon Laws 2022. [https://www.oregonlegislature.gov/bills\\_laws/ors/ors430.html](https://www.oregonlegislature.gov/bills_laws/ors/ors430.html).

<sup>4</sup> Oregon Health Authority. "2023-2024 Oregon Opioid Settlement Spending Report."

<https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/SUBSTANCEUSE/OPIOIDS/Documents/opioid-settlement-spending-report-fy-2023-24.pdf>.

<sup>5</sup> Treatment Advocacy Center. "Oregon Psychiatric Beds Report." 2023. [https://www.tac.org/wp-](https://www.tac.org/wp-content/uploads/2023/10/Oregonbedsinformation.pdf)

[content/uploads/2023/10/Oregonbedsinformation.pdf](https://www.tac.org/wp-content/uploads/2023/10/Oregonbedsinformation.pdf).

<sup>6</sup> United States Census Bureau, "2023 American Community Survey – Total Population."

[https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US\\$0400000](https://data.census.gov/table/ACSDT1Y2023.B01003?q=population&t=Population+Total&q=010XX00US$0400000).

<sup>7</sup> Silver, Shanti, "Estimating Psychiatric Bed Need in the United States," p. 2-4. Treatment Advocacy Center Office of Research and Public Affairs. January 2024. [https://www.tac.org/wp-content/uploads/2024/03/TAC\\_ORPA\\_ResearchSummary1.24.pdf](https://www.tac.org/wp-content/uploads/2024/03/TAC_ORPA_ResearchSummary1.24.pdf).